Yu Wang, M.D./Ph.D., is GenFleet's Chief Medical Officer and responsible for GenFleet's clinical development strategy and execution, as well as the company's whole R&D strategy and project planning. Dr. Wang possesses profound expertise in anti-tumor therapeutics. His extensive background spans the development of chemotherapy agents, targeting agents, therapeutic vaccines, oncolytic virus therapies, checkpoint inhibitors, and cell therapies for treating both solid tumors and hematological malignancies.
Dr. Wang received a doctorate degree in Surgery from Shanghai Medical University (now School of Medicine, Fudan University), and completed postdoctoral training at Barbara Karmanos Cancer Institute（Wayne State University, Michigan）. In China, he worked with multinational pharmaceutical companies (Eli Lilly, GSK, Sanofi APTSU and Novartis) directing full clinical development of oncology products. As a program leader of Translational Clinical Oncology at Novartis, Dr. Wang took part in the clinical studies of several innovative drugs later approved globally. Prior to his role at GenFleet, he was the co-founder of ZenRhyme Advisory, serving as a part-time Chief Medical Officer or senior consultant for biotech and pharmaceutical companies.
